MEDICINOVA INC
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
DE
Business Address
4275 EXECUTIVE SQUARE, LA JOLLA, CA, 92037
Mailing Address
4275 EXECUTIVE SQUARE, LA JOLLA, CA, 92037
Phone
858-373-1500
Fiscal Year End
1231
EIN
330927979
Financial Overview
FY2025
$4.02M
Total Liabilities
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 10-K Annual financial report | March 10, 2026 | View on SEC |
| 8-K Current report of material events | February 20, 2026 | View on SEC |
| 4 Insider stock transaction report | January 20, 2026 | View on SEC |
| 4 Insider stock transaction report | January 20, 2026 | View on SEC |
| 424B5 Prospectus supplement | December 30, 2025 | View on SEC |
| 8-K Current report of material events | December 30, 2025 | View on SEC |
| S-3 Shelf registration for future offerings | December 5, 2025 | View on SEC |
| 10-Q Quarterly financial report | November 12, 2025 | View on SEC |
| S-1 IPO registration statement | August 22, 2025 | View on SEC |
| 10-Q Quarterly financial report | August 14, 2025 | View on SEC |
Annual Reports
10-K
March 10, 2026
- Positive Phase 2b SPRINT-MS trial for MN-166 in progressive MS, demonstrating significant reduction in brain atrophy and good safety.
- MN-166 (ibudilast) offers unique neuroprotective and anti-inflammatory properties for multiple neurological and inflammatory conditions.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.